Company Profile

Loading... Please wait.


Date Title
23 Jun 2017 IPO Valbiotis expand

Listing of Valbiotis on Euronext

Sébastien Peltier, CEO of Valbiotis, opens the trading day in Paris.

Valbiotis is a biopharmaceutical company specializing in the research and development of preventive and therapeutic products based on polymolecular complexes indicated at specific stages of progression of chronic metabolic pathologies such as type 2 diabetes, obesity, dyslipidemia or NASH (Non-Alcoholic Steatosis Hepatic).

07 Jun 2017 Valbiotis lists on Euronext Growth expand

€11.5 million raised; market capitalisation above €37 million

Paris – 7 June 2017 Euronext today welcomes Valbiotis, a company specialised in research and development in medical nutrition, to its Euronext Growth[1] market in Paris.

An innovative company based in La Rochelle, Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for affected patients. Its plant-based products are scientifically and clinically developed for manufacturers in the agro-food and pharmaceutical industries. The company works alongside academic research centres of excellence to help fight against diabetes, obesity, cardio-vascular disease and non-alcoholic steato-hepatitis (NASH).

Valbiotis (ticker code: ALVAL) was listed through the admission to trading on June 7, 2017 of 3 547 936 shares including 1 095 238 new shares issued through a Global Offering[2] including the extension option.

The offering price was set at €10,5 per share. Market capitalisation was above €37 million on the day of listing, and the transaction raised a total of €11.5 million. 

Sébastien Peltier, Chairman and CEO of Valbiotis, said: “We are very proud to announce our successful listing today on Euronext Growth, and would like to thank all of the shareholders and investors—French and international individuals and institutions—that have given us their trust and support. Listing is a key step in our development, and the funds raised will enable Valbiotis to step up the pace of its pre-clinical and clinical programs. We will also be able to bring our technical platform and external partners in-house, and accelerate our search for partnerships with leading players in the pharmaceutical and food industries.”

Euronext is now Europe’s leading stock exchange for the listings of European technology companies, covering a wide range of sectors from digital to software, media and eco-industries. With today’s listing, Valbiotis joins the family of 81 life sciences SMEs already listed on Euronext, which together represents a total capitalisation of nearly €13  billion. 


[1] The « Alternext » market will become « Euronext Growth » from 19 June 2017.

[2] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.